# ğŸ“… Daily Report - 2026-02-06

> ä»Šæ—¥ç­›é€‰å‡º **58** æ¡å†…å®¹ï¼Œæ¥è‡ª **3** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºFontanç›¸å…³è‚ç—…è‚ç»†èƒä»£è°¢é‡ç¼–ç¨‹ï¼›NanoString GeoMx DSPæŠ€æœ¯é‡å¡‘èƒ°è…ºè‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼Œå¢å¼ºæŠ—è‚¿ç˜¤å…ç–«ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- ç»“ç›´è‚ ç™Œå¹²ç»†èƒçš„åŸºå› ç»„ä¸å…ç–«å­¦åˆ†æï¼Œè°ƒæ§å¹²æ€§ä¸å…ç–«åº”ç­”ã€‚
- è‚ºç™Œä¸­p53çªå˜ä½“ç‹¬ç‰¹çš„å¤±æ´»æœºåˆ¶åŠå…¶è½¬å½•æ¿€æ´»æŠ‘åˆ¶ã€‚
- èƒ°è…ºå¯¼ç®¡å†…ä¹³å¤´çŠ¶é»æ¶²ç˜¤ (IPMN) çš„ç©ºé—´åˆ†æï¼Œè¯†åˆ«å…·æœ‰æ¶æ€§ç‰¹å¾çš„ä½çº§åˆ«ä¸Šçš®ç»†èƒã€‚
- é˜¿å°”èŒ¨æµ·é»˜ç—…ç ”ç©¶ï¼Œé‰´å®šä¿å®ˆçš„AÎ²å“åº”è›‹ç™½ç»„åŠç—…ç†ä¿®é¥°å› å­ã€‚
- å„¿ç«¥ç”²çŠ¶è…ºç™Œä¾µè¢­æ€§çš„DNAç”²åŸºåŒ–åˆ†å±‚ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- ç©ºé—´è½¬å½•ç»„å­¦ (Single-cell Spatial Transcriptomics) å’Œæ•°å­—ç©ºé—´åˆ†æ (NanoString GeoMx Digital Spatial Profiling)ã€‚
- æ•´åˆè›‹ç™½è´¨ç»„å­¦ (Integrative proteomics) å’Œæ¯”è¾ƒå•ç»†èƒè½¬å½•ç»„å­¦ (Comparative single-cell transcriptomics)ã€‚

### ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
OpenAI Codexé©±åŠ¨çš„RåŒ…é‡æ„ï¼Œå°†æ—§çš„`qqman` RåŒ…å‡çº§è‡³`ggplot2`ï¼Œå®ç°äº†ä»£ç çš„è‡ªåŠ¨åŒ–æ›´æ–°ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   åˆ©ç”¨AIè¾…åŠ©è¿›è¡ŒRè¯­è¨€åŒ…çš„ç°ä»£åŒ–æ”¹é€ ã€‚
*   å°†åŸºäº`lattice`ç»˜å›¾çš„`qqman`åŒ…è¿ç§»è‡³æ›´ç°ä»£çš„`ggplot2`ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   åº”ç”¨OpenAI Codexè¿›è¡Œä»£ç çš„è‡ªåŠ¨è¿ç§»å’Œæ›´æ–°ã€‚
*   é€šè¿‡â€œplan+executeâ€çš„ç­–ç•¥ï¼Œé«˜æ•ˆå®Œæˆä»£ç åº“çš„é‡æ„ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ADAM-tRNA-seq ä¼˜åŒ–äº†ç›´æ¥ tRNA æµ‹åºæµç¨‹ï¼Œå®ç°äº†æ›´ç²¾ç¡®çš„å»é‡å’Œå±‚çº§æ¯”å¯¹ï¼Œæ˜¾è‘—æå‡äº† tRNA ä¸°åº¦å’Œå¤šæ ·æ€§çš„é‡åŒ–èƒ½åŠ›ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- ç›´æ¥ Nanopore æµ‹åºåˆ†æè½¬ç§» RNA (tRNA)
- ç²¾ç¡®é‡åŒ– tRNA çš„ä¸°åº¦ä¸å¤šæ ·æ€§

**æŠ€æœ¯äº®ç‚¹**ï¼š
- ä¼˜åŒ–çš„ RNA æµ‹åºå·¥ä½œæµç¨‹
- åˆ›æ–°çš„å»é‡ä¸å±‚çº§æ¯”å¯¹ç­–ç•¥

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (56æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE310443 å•ç»†èƒç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºFontanç›¸å…³è‚ç—…ä¸­è‚ç»†èƒä»£è°¢é‡ç¼–ç¨‹**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolicã€single-cellã€spatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributors : Brandon M Lehrich ; Jordann N Lewis ; Vik Meadows ; Lori Schmitt ; Mylarappa B Ningappa ; Jia-Jun Liu ; Silvia Liu ; Catherine Gestrich ; Victor O Morell ; Rakesh Sindhi ; Satdarshan P Monga ; Anita SarafSeries Type : OtherOrganism : Homo sapiensBackground: Fontan-associated liver disease (FALD) is a common sequelae of single-ventricle patients palliated with the Fontan operation. FALD severity can impact clinical decisions; however, the pathophysiology of FALD progression is unknown. Methods: Single-cell spatial transcriptomics (ST) was performed on liver explant tissue sections from FALD patients with early and advanced fibrosis using CosMxTM Spatial Molecular Imaging with in-situ hybridization of 6000 genes (n=2). Immunofluorescence for hepatic zonation and cellular stress markers was used to confirm protein expression based on ST analysis in biopsy and explant FALD tissues (n=17). Results: Unbiased clustering yielded 12 liver cell types, comprising five subtypes of hepatocytes. FALD with advanced fibrosis demonstrated the expansion of mid-zonal hepatocytes, accompanied by the loss of metabolic markers associated with canonical pericentral and periportal hepatocytes. Advanced FALD hepatocytes uniquely demonstrated increased cellular stress and a redundant metabolic phenotype. Advanced FALD hepatocytes changed into a senescent-like state, which we have termed hepatocyte metabolic exhaustion. Protein expression analysis confirmed metabolic exhaustion within hepatocytes and upregulation of cellular stress markers in advanced FALD tissue specimens. Immunofluorescence staining of FALD samples demonstrated a disruption of zonation and a significant increase in heat shock protein 70 (HSP70). HSP70 expression strongly correlated with the congestive hepatic fibrosis (CHF) score. Conclusions: Single-cell ST has identified a population of hepatocytes with features of metabolic exhaustion and cellular stress unique to advanced FALD.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310443)

**2.** â­ **GSE313657 é¢„åº·å¤ä½œä¸ºä¸€ç§ç”Ÿç‰©æ´»æ€§å¹²é¢„æªæ–½ï¼Œå¯é‡å¡‘èƒ°è…ºè‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼Œä»è€Œå¢å¼ºæŠ—è‚¿ç˜¤å…ç–«åŠ›**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€immuneã€immunity
- ğŸ“ **æè¿°**ï¼šContributors : Hong Zhao ; Renee StubbinsSeries Type : OtherOrganism : Homo sapiens ; synthetic constructThis dataset contains NanoString GeoMx Digital Spatial Profiling data generated from surgically resected pancreatic ductal adenocarcinoma (PDAC) specimens collected from patients who underwent a multimodal prehabilitation program and matched untreated controls. Spatial transcriptomic profiling was performed across immune (CD45 positive), tumor (PanCK positive), and stromal regions of interest to investigate the biological effects of prehabilitation on the PDAC tumor microenvironment. Differential expression, pathway enrichment, and immune deconvolution analyses were used to evaluate transcriptional changes associated with cytotoxic immune activation, stromal remodeling, and oncogenic signaling. The goal of this exploratory dataset is to provide an initial resource for investigating how prehabilitation may influence immuneâ€“tumor interactions in PDAC and to support future studies integrating biological and clinical endpoints.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313657)

**3.** â­ **GSE288874 ç»“ç›´è‚ ç™Œèµ·å§‹ç»†èƒçš„æ•´åˆåŸºå› ç»„å­¦å’ŒåŠŸèƒ½å…ç–«å­¦åˆ†æï¼Œä»¥è°ƒèŠ‚å¹²æ€§ç‰¹æ€§å’Œå¯¹å…ç–«ååº”çš„æ•æ„Ÿæ€§ [RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€immuneã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Cristina Maccalli ; Alex Tout ; Salim BougarnSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe conducted a Total RNAseq profiling of primary CICs-CRC and differentiated tumor cell lines-CRC (FBS), including autologous pairs. A differential gene expression profile was detected in CICs vs. FBS tumor cells. Overall, N=1187 were detected out of a total of 15,913 genes with measured expression as differentially expressed with p<0.05. Through applying the threshold of p<0.01and LogFC of 1.5, N=132 genes resulted as significantly differentially expressed in CICs as compared to FBS tumor cells. In summary, 33 pathways were found to be signiï¬cantly impacted highlighting the hub function of differentially expressed genes (DEGs) (N=40) and significant pathways (N=26) (p<0.05). The differentially expressed genes include genes related to cancer development and progression, e.g., the unfolded protein response component CHAC1 as well as the hexokinase domain component 1, HKDC1 which promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression. Moreover, aldolase, fructose-bisphosphate C (ALDOC), that is associated with tumor cell spheroids formation, was 2.5-fold upregulated in CICs compared to FBS tumor cells while LCK kinase, implicated in various oncogenic processes, particularly in colorectal cancer was 5-fold upregulated in CICs. On the other hand, JUNB, a direct target of TGF-Î²-Smad signaling, which can act as tumor suppressor or oncogene depending on the cancer entity was found to be downmodulated in CRC-CICs vs. -FBS tumor cell lines.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288874)

**4.** **GSE318294 è‚ºç™Œå¯Œé›†çš„ p53 çªå˜ä½“å æ®ç»å…¸çš„ p53 é¶åŸºå› ï¼Œä½†å¹¶ä¸æ¿€æ´»è½¬å½•ï¼Œæ­ç¤ºäº†ä¸€ç§ç‹¬ç‰¹çš„å¤±åŠŸèƒ½è¡Œä¸º [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Mason A Tracewell ; Hailey N Shankle ; Samantha M Barnada ; Khushali S Vyas ; Kevin M Kim ; Theodhora Qyshkollari ; Jonathan E Karlin ; Julie A Barta ; Steven B McMahonSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensLung cancer is the most common cause of cancer-related death in the U.S. and globally. Cigarette smoking remains the leading risk factor for lung cancer, in part by inducing loss-of-function mutations in tumor suppressor genes, including TP53. While most cancers share a set of common â€œhotspotâ€ mutations in p53, lung cancer exhibits an additional, distinct cluster of hotspot mutations. This cluster is typified by the missense mutations TP53:p.V157F and TP53:p.R158L. While canonical hotspot mutations cause broad misfolding of p53 or eliminate specific DNA contact residues, mechanistic studies of the lung cancer mutants reported here demonstrate that they retain the ability to bind the same genomic sites as wild-type p53. Despite actively binding to traditional p53 target genes, the lung cancer mutants are defective in activating transcription. To our knowledge, this represents the first demonstration of functional inactivation of the p53 tumor suppressor at a point after DNA binding, but prior to target gene activation. Relevant to the sequential inactivation of each p53 allele during cancer progression, the lung cancer mutants block the activity of a wild-type p53 allele when co-expressed in a dominant negative manner. Identification of this loss-of-function mechanism has key implications for therapeutic strategies aimed at restoring p53 function in lung cancer.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318294)

**5.** **GSE318292 è‚ºç™Œå¯Œé›†çš„ p53 çªå˜ä½“å æ®ç»å…¸çš„ p53 é¶åŸºå› è€Œä¸æ¿€æ´»è½¬å½•ï¼Œæ­ç¤ºäº†ä¸€ç§ç‹¬ç‰¹çš„å¤±åŠŸèƒ½è¡Œä¸º [ChIP-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€ChIP-seq
- ğŸ“ **æè¿°**ï¼šContributors : Mason A Tracewell ; Hailey N Shankle ; Samantha M Barnada ; Khushali S Vyas ; Kevin M Kim ; Theodhora Qyshkollari ; Jonathan E Karlin ; Julie A Barta ; Steven B McMahonSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensLung cancer is the most common cause of cancer-related death in the U.S. and globally. Cigarette smoking remains the leading risk factor for lung cancer, in part by inducing loss-of-function mutations in tumor suppressor genes, including TP53. While most cancers share a set of common â€œhotspotâ€ mutations in p53, lung cancer exhibits an additional, distinct cluster of hotspot mutations. This cluster is typified by the missense mutations TP53:p.V157F and TP53:p.R158L. While canonical hotspot mutations cause broad misfolding of p53 or eliminate specific DNA contact residues, mechanistic studies of the lung cancer mutants reported here demonstrate that they retain the ability to bind the same genomic sites as wild-type p53. Despite actively binding to traditional p53 target genes, the lung cancer mutants are defective in activating transcription. To our knowledge, this represents the first demonstration of functional inactivation of the p53 tumor suppressor at a point after DNA binding, but prior to target gene activation. Relevant to the sequential inactivation of each p53 allele during cancer progression, the lung cancer mutants block the activity of a wild-type p53 allele when co-expressed in a dominant negative manner. Identification of this loss-of-function mechanism has key implications for therapeutic strategies aimed at restoring p53 function in lung cancer.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318292)

**6.** **GSE316796 IPMN çš„ç©ºé—´åˆ†æå®šä¹‰äº†å…·æœ‰æ¶æ€§ç‰¹å¾çš„çŸ›ç›¾çš„ KRT17 é˜³æ€§ä½çº§åˆ«ä¸Šçš®ç»†èƒç¾¤ [scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šscRNAã€spatial
- ğŸ“ **æè¿°**ï¼šContributor : Eileen S CarpenterSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground & Aims:Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that represent one of the few radiologically identifiable precursors to pancreatic ductal adenocarcinoma (PDAC). Though the IPMN-bearing patient population represents a unique opportunity for early detection and interception, current guidelines provide insufficient accuracy in determining which patients should undergo resection versus surveillance, resulting in a sizable fraction of resected IPMNs only harboring low-grade dysplasia, suggesting that there may be overtreatment of this clinical entity.Methods:To investigate the transcriptional changes that occur during IPMN progression, we performed spatial transcriptomics using the Nanostring GeoMx on patient samples containing the entire spectrum of IPMN disease including low-grade dysplasia, high-grade dysplasia, and IPMN-derived carcinoma. Single cell RNA sequencing was performed on side branch and main duct IPMN biospecimens.Results:We identified a subpopulation of histologically low-grade IPMN epithelial cells that express malignant transcriptional features including KRT17, S100A10 and CEACAM5, markers that are enriched in PDAC. We validated this high-risk gene signature in both single-cell RNA sequenced samples and an external ST dataset containing a larger number of IPMN samples including non-tumor bearing IPMN (i.e. low-grade IPMN in isolation). Immunofluorescence staining of a large cohort of patient tissues confirmed the presence of KRT17-positive cells, which were found to comprise a small subset of epithelial cells within histologically low-grade IPMN in a patchy distribution.Conclusions:Our study demonstrates that KRT17 marks a distinct transcriptional signature in a subpopulation of epithelial cells within histologically low-grade IPMN. This population of cells likely represents a transitional state of histologically low-grade epithelial cells undergoing progression to a higher grade of dysplasia and thus may represent a higher risk of progression to carcinoma.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316796)

**7.** **GSE318214 æ•´åˆè›‹ç™½è´¨ç»„å­¦é‰´å®šå‡ºé˜¿å°”èŒ¨æµ·é»˜ç—…ä¸­ä¿å®ˆçš„AÎ²æ·€ç²‰æ ·è›‹ç™½ååº”ä½“ã€æ–°å‹æ–‘å—è›‹ç™½å’Œç—…ç†ä¿®é¥°å› å­**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šAlzheimerã€proteomics
- ğŸ“ **æè¿°**ï¼šContributors : Karen N McFarland ; Yona Levites ; Todd E GoldeSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAlzheimerâ€™s disease (AD) is a complex neurodegenerative disorder that develops over decades. AD brain proteomics reveals vast alterations in protein levels and numerous altered biologic pathways. Here, we compare AD brain proteome and network changes with the brain proteomes of amyloid b (Ab)-depositing mice to identify conserved and divergent protein networks with the conserved networks identifying an Ab amyloid responsome. Proteins in the most conserved network (M42) accumulate in plaques, cerebrovascular amyloid (CAA), and/or dystrophic neuronal processes, and overexpression of two M42 proteins, midkine (Mdk) and pleiotrophin (PTN), increases the accumulation of Ab in plaques and CAA. M42 proteins bind amyloid fibrils in vitro, and MDK and PTN co-accumulate with cardiac transthyretin amyloid. M42 proteins appear intimately linked to amyloid deposition and can regulate amyloid deposition, suggesting that they are pathology modifiers and thus putative therapeutic targets. We posit that amyloid-scaffolded accumulation of numerous M42+ proteins is a central mechanism mediating downstream pathophysiology in AD.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318214)

**8.** **GSE314373 singISTï¼šä¸€ç§ç”¨äºæ¯”è¾ƒç–¾ç—…æ¨¡å‹å’Œäººç±»å•ç»†èƒè½¬å½•ç»„å­¦çš„æ•´åˆæ–¹æ³•**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsingle-cellã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributors : Johann E Gudjonsson ; Lam C TsoiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDisease models are fundamental tools in drug discovery and early-stage drug development, but they only approximate human disease, and selecting a suitable model is challenging. Quantitative computational methods exist to assess molecular resemblance to human conditions, but approaching that work at single-cell resolution, and doing so in an explainable and generalizable way, remain very limited. We present singIST, a computational method for comparative single-cell transcriptomics analysis between disease models and human conditions. singIST provides explainable quantitative measures on disease model similarity to the human reference at the pathway, cell type and gene levels. These measures jointly account for gene orthology, cell type presence in the model, cell type and gene importance in the human condition, and gene level fold changes in the model, within a unifying framework that controls for the intrinsic complexities of single-cell data. We first test singIST in three well-characterized murine models against moderate-to-severe Atopic Dermatitis, showing that it recapitulates established biology while generating new hypotheses. We then apply it to Hidradenitis Suppurativa, comparing in vivo human lesions with ex vivo skin explants with and without CD3/CD28 stimulation, and show that stimulation selectively improves pathways that already recapitulate the human signal. Finally, we perform simulation studies that: (i) unit-test the implementation and behaviour of the algorithm under controlled scenarios and (ii) compare singIST against a naÂ¨Ä±ve baseline based on overlapping differentially expressed genes.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314373)

**9.** **GSE312914 åŸºäºDNAç”²åŸºåŒ–çš„å„¿ç«¥ç”²çŠ¶è…ºç™Œä¾µè¢­æ€§åˆ†å±‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcarcinomaã€methylation
- ğŸ“ **æè¿°**ï¼šSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312914)

**10.** **GSE312587 åŸºäºDNAç”²åŸºåŒ–çš„å„¿ç«¥ç”²çŠ¶è…ºç™Œä¾µè¢­æ€§åˆ†å±‚[ç¬¬äºŒæ‰¹]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcarcinomaã€methylation
- ğŸ“ **æè¿°**ï¼šContributors : Jenny Z Li ; Julio R Filho ; Andrew J Bauer ; Aime T Franco ; Wanding ZhouSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensAccurate triage of pediatric thyroid carcinomas requires reliable biomarkers of tumor invasiveness. DNA methylation, a proven molecular analyte for cancer classification, offers potential for stratifying thyroid carcinoma behavior. In a cohort of 88 patients, we identified distinct methylation profiles associated with both tumor invasiveness and driver mutations, such as BRAF p.V600E, Ras-like, kinase fusions, and DICER1 mutations. Differentially methylated regions implicate immune infiltration and disrupted thyroid tissue development and function, implicating nuclear receptor, Hippo, and AP1 signaling pathways. Using these features, we developed accurate classifiers for tumor invasiveness and driver mutation groups. Our findings highlight the clinical utility of DNA methylation profiling for risk stratification and prognostic assessment in pediatric thyroid cancers.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312587)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 46 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (1æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰

**1.** **è½¬å‘ï¼šOpenAI Codex Appï¼šVibe - ä½¿ç”¨ plan+execute å°†æˆ‘çš„æ—§ qqman R åŒ…æ›´æ–°ä¸º ggplot2ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šR package
- ğŸ“ **æè¿°**ï¼šReposted from the original at https://blog.stephenturner.us/p/openai-codex-app-qqman.Earlier this week I reposted a Bluesky post from Ethan Mollick. Iâ€™m on the same page here â€” there are problems for sure, but these tools have irreversibly changed th... Continue reading: Repost: OpenAI Codex App: Vibe-updating my old qqman R package to ggplot2 with plan+execute.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.r-bloggers.com/2026/02/repost-openai-codex-app-vibe-updating-my-old-qqman-r-package-to-ggplot2-with-planexecute/)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰

**1.** **ADAM-tRNA-seqâ€”â€”ä¸€ç§ç”¨äºç›´æ¥tRNAæµ‹åºä¸­è§£å¤ç”¨å’Œå¢å¼ºå±‚çº§æ˜ å°„çš„ä¼˜åŒ–æ–¹æ³•**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencing
- ğŸ“ **æè¿°**ï¼šAn optimized RNA sequencing workflow improves direct Nanopore analysis of transfer RNAs, enabling accurate demultiplexing and hierarchical mapping to better quantify tRNA abundance and diversity...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/adam-trna-seq-an-optimized-approach-for-demultiplexing-and-enhanced-hierarchal-mapping-in-direct-trna-sequencing/)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| RNA-seq | 10 |
| cancer | 6 |
| scRNA | 5 |
| carcinoma | 5 |
| methylation | 5 |
| spatial | 4 |
| immune | 4 |
| clustering | 4 |
| transcriptomics | 3 |
| Alzheimer | 3 |
| single-cell | 3 |
| ChIP-seq | 2 |
| genome | 2 |
| ATAC-seq | 2 |
| metabolic | 2 |
| pathway | 2 |
| glioma | 2 |
| cardiac | 2 |
| sequencing | 1 |
| R package | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (46æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE300358 TGFÎ²ä¿¡å·é€šè·¯é€šè¿‡SOX4è½¬å½•è°ƒæ§ä¿ƒè¿›ä¹³è…ºç™Œç»†èƒçš„ç»†èƒå‘¨æœŸè¿›ç¨‹å’Œå¯¹CDK4/6æŠ‘åˆ¶å‰‚å¸•åšè¥¿å°¼çš„è€è¯æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300358)
- [GSE296440 åŸºäºDNAç”²åŸºåŒ–çš„å„¿ç«¥ç”²çŠ¶è…ºç™Œä¾µè¢­æ€§åˆ†å±‚[ç¬¬ä¸€æ‰¹]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296440)
- [GSE314660 é‰´å®šä¸œäºšè‚ºè…ºç™Œé£é™©çš„è¡¨è¾¾å’Œ DNA ç”²åŸºåŒ–ç”Ÿç‰©æ ‡å¿—ç‰© [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314660)
- [GSE318278 ä¸‰ä¸ª CBX2 åˆ†å­çš„è‡ªèšé›†é©±åŠ¨ PRC2 ä¿ƒè¿› Polycomb é¶åŸºå› çš„å…¼æ€§å¼‚æŸ“è‰²è´¨åŒ– [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318278)
- [GSE318277 ä¸‰ä¸ª CBX2 åˆ†å­çš„è‡ªèšé›†é©±åŠ¨ PRC2 ä¿ƒè¿› Polycomb é¶åŸºå› çš„å…¼æ€§å¼‚æŸ“è‰²è´¨åŒ– [Hi-C]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318277)
- [GSE305695 IRE1Î± é€šè¿‡ NR1D1 mRNA é™è§£å’Œæº¶é…¶ä½“ç”Ÿç‰©åˆæˆè°ƒèŠ‚å…ç–«æ€§è¡€å°æ¿å‡å°‘ç—‡ä¸­çš„å·¨å™¬ç»†èƒåå™¬ä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305695)
- [GSE237065 mTORä¿¡å·é€šè·¯è°ƒæ§æœè‡å¹¼è™«ä¸­æœ‰æ•ˆç»†èƒå…ç–«ååº”æ‰€éœ€çš„éœ€æ±‚é€‚åº”æ€§é€ è¡€å’Œä»£è°¢é‡ç¼–ç¨‹](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237065)
- [GSE317790 å…ˆå¯¼ç»†èƒçš„é˜¶æ®µç‰¹å¼‚æ€§è½¬å½•ç»„å­¦æ­ç¤ºäº†é©±åŠ¨é›†ä½“å…¥ä¾µçš„ç»†èƒæœºåˆ¶](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317790)
- [GSE316928 è¡¨å¾å¤§è„‘ä¸­å°èƒ¶è´¨ç»†èƒã€æ˜Ÿå½¢èƒ¶è´¨ç»†èƒå’Œç¥ç»å…ƒåœ¨å¥åº·ã€è¡°è€å’Œç–¾ç—…çŠ¶æ€ä¸‹çš„ä»£è°¢ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316928)
- [GSE316003 IPMNç©ºé—´åˆ†ææ­ç¤ºäº†ä¸€ç§çŸ›ç›¾çš„KRT17é˜³æ€§ä½çº§åˆ«ä¸Šçš®ç»†èƒç¾¤ï¼Œè¯¥ç»†èƒç¾¤å…·æœ‰æ¶æ€§ç‰¹å¾ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316003)
- [GSE308455 åŸºå› ç»„ç¼–è¾‘èƒ†ç®¡ç™Œç±»å™¨å®˜ä¸­BAP1çªå˜çš„åŠŸèƒ½è¡¨å¾ï¼šåœ¨ç»†èƒæ­»äº¡å’Œè¯ç‰©ååº”ä¸­çš„ä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308455)
- [GSE303857 çƒ­ä¼‘å…‹åé€šè¯»è½¬å½•è¿‡ç¨‹ä¸­ CPSF73 æ¿€æ´»å’Œ 3' Pol II æš‚åœæ¶ˆå¤± [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303857)
- [GSE303856 çƒ­ä¼‘å…‹åé€šè¯»è½¬å½•è¿‡ç¨‹ä¸­ CPSF73 æ¿€æ´»å’Œ 3' Pol II æš‚åœæ¶ˆå¤± [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303856)
- [GSE299895 è½¬å½•èƒ½åŠ›å†³å®šäº†åˆ†ç¦»çš„MSRæ‹·è´çš„å¼‚æŸ“è‰²è´¨æˆæ ¸æ½œåŠ›ã€‚[RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299895)
- [GSE318420 åœ¨ç´¢æ‹‰éå°¼è”åˆçº³æ­¦åˆ©å°¤å•æŠ—çš„ II æœŸä¸´åºŠè¯•éªŒä¸­ï¼Œè‚åŠŸèƒ½éšœç¢çš„è‚ç»†èƒç™Œæ‚£è€…ä½“å†…å…ç–«æŠ‘åˆ¶æ€§å•æ ¸ç»†èƒå¯Œé›†](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318420)
- [GSE318268 CMSäºšå‹ä¸ç›´è‚ ç™Œæ–°è¾…åŠ©Galunisertibè”åˆæ”¾åŒ–ç–—è¯•éªŒä¸­çš„å®Œå…¨ç¼“è§£ç›¸å…³](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318268)
- [GSE318059 ç¯å¢ƒè¯±å¯¼çš„è¡¨è§‚é—ä¼ è·¨ä»£é—ä¼ æˆäººå‘ç—…ç–¾ç—…çš„ä¸–ä»£ç¨³å®šæ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318059)
- [GSE317068 éª¨éª¼ç–¾ç—…ç»†èƒå’Œé—ä¼ å†³å®šå› ç´ çš„å¤šå°ºåº¦åˆ†æå’ŒåŠŸèƒ½éªŒè¯ [äººç±»å•ç»†èƒRNAæµ‹åº]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317068)
- [GSE316715 IAP é€†è½¬å½•è½¬åº§å­ä¿ƒè¿›å°é¼ èƒç›˜çš„è½¬å½•å¤šæ ·æ€§ [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316715)
- [GSE316711 IAP é€†è½¬å½•è½¬åº§å­ä¿ƒè¿›å°é¼ èƒç›˜çš„è½¬å½•å¤šæ ·æ€§ [ATAC-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316711)
- [GSE315592 å¤§è„‚è‚ªç»†èƒå¢åŠ å›Šæ³¡ä»‹å¯¼çš„è„‚è´¨é‡Šæ”¾å¹¶ä¿ƒè¿›ä¹³è…ºç™Œæ¶æ€§è½¬åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315592)
- [GSE311545 é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³ circPDE4B ä¸ GEMIN5 ç›¸äº’ä½œç”¨ä»¥è°ƒèŠ‚ç¿»è¯‘](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311545)
- [GSE302937 é˜¿å°”èŒ¨æµ·é»˜ç—…æ‚£è€…çš„äººç±»é¼»å†…å—…è§‰æ´»æ£€åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302937)
- [GSE294059 è„“æ¯’ç—‡æ‚£è€…å’Œéè„“æ¯’ç—‡å¯¹ç…§ç»„å¤–å‘¨è¡€å•æ ¸ç»†èƒçš„RNAæµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294059)
- [GSE293190 æœ¨çŠ€è‰ç´ æŠ‘åˆ¶ç±»é£æ¹¿å…³èŠ‚ç‚ä¸­ Th17 ç»†èƒåˆ†åŒ–å’Œè„Šé«“æµ¸æ¶¦ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293190)
- [GSE290684ï¼šå…¨é¢çš„å•ç»†èƒåˆ†ææ­ç¤ºäº†TPPUåœ¨ç¼“è§£è„“æ¯’ç—‡ç›¸å…³æ€¥æ€§è‚æŸä¼¤ä¸­çš„å…ç–«è°ƒèŠ‚æœºåˆ¶](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290684)
- [GSE290455 æ¿€æ´»çš„ CD8+ T ç»†èƒï¼ˆæœ‰æˆ–æ— è°·æ°¨é…°èƒºåˆæˆé…¶ï¼‰çš„ RNA æµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290455)
- [GSE285954 RNA-seq åˆ†æäº† RAW264.7 ä¸­ Dpep2 æ•²ä½çš„æƒ…å†µã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285954)
- [GSE278461 ç‹¬ç«‹çš„è½¬å½•å’Œå‰ªæ¥åŸºå› ç½‘ç»œé€šè¿‡ pRb-E2F é€šè·¯ç›¸äº’è¿æ¥å’Œåè°ƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278461)
- [GSE212817 éª¨éª¼ç–¾ç—…ç»†èƒå’Œé—ä¼ å†³å®šå› ç´ çš„å¤šå°ºåº¦åˆ†æå’ŒåŠŸèƒ½éªŒè¯ [å°é¼ å•ç»†èƒRNAæµ‹åº]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE212817)
- [GSE314841 é‰´å®šä¸œäºšè‚ºè…ºç™Œé£é™©çš„è¡¨è¾¾å’ŒDNAç”²åŸºåŒ–ç”Ÿç‰©æ ‡å¿—ç‰©[DNAç”²åŸºåŒ–èŠ¯ç‰‡]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314841)
- [GSE313764 çº¿ç²’ä½“è½¬ç§»è‡³ç²’ç»†èƒé«“ç³»æ¥æºçš„æŠ‘åˆ¶ç»†èƒå¯å¢å¼ºå…ç–«æŠ‘åˆ¶æ´»æ€§ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313764)
- [GSE318441 æ–‘ç‚¹å®šä½æ¿€é…¶TAOK2å¯¹æ ¸RNAåŠ å·¥çš„åè°ƒä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318441)
- [GSE318347 å°åˆ†å­å¯¼å‘çš„æµ¸æ²¡åŸ¹å…»äººé¼»æ°”é“ä¸Šçš®åˆ†åŒ–ç”¨äºå‘¼å¸ç³»ç»Ÿç–¾ç—…å»ºæ¨¡ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318347)
- [GSE318298 åˆ©ç”¨ CUT-taq æ£€æµ‹é‡ç”Ÿå‹ C57BL/6J éª¨é«“æ¥æºå·¨å™¬ç»†èƒä¸­ EGR1 å…¨åŸºå› ç»„æŸ“è‰²è´¨å ä½æƒ…å†µ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318298)
- [GSE318286 SAGA/ATACå¤åˆç‰©ç»´æŒå¼‚å¸¸æŸ“è‰²è´¨è°ƒæ§å¹¶ä¿ƒè¿›å¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤çš„è‚¿ç˜¤å‘ç”Ÿ[CUT&Run]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318286)
- [GSE318284 Acsl1 ä»‹å¯¼çš„ FA åˆæˆæŸå®³ I å‹ç³–å°¿ç—…çš„éª¨æ•´åˆ [ATAC-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318284)
- [GSE318279 ä¸‰ä¸ª CBX2 åˆ†å­çš„è‡ªèšé›†é©±åŠ¨ PRC2 ä¿ƒè¿› Polycomb é¶åŸºå› çš„å…¼æ€§å¼‚æŸ“è‰²è´¨åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318279)
- [GSE318276 ä¸‰ä¸ª CBX2 åˆ†å­çš„è‡ªèšé›†é©±åŠ¨ PRC2 ä¿ƒè¿› Polycomb é¶åŸºå› çš„å…¼æ€§å¼‚æŸ“è‰²è´¨åŒ– [Cut & Run, Cut & Tag]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318276)
- [GSE318243 ç¼ºæ°§è¯±å¯¼çš„lncRNAåœ¨è‚ç»†èƒç™Œé“æ­»äº¡è°ƒæ§ä¸­çš„ä½œç”¨å’Œæœºåˆ¶](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318243)
- [GSE317049 æµ·è—»é…¸é’ é€šè¿‡ PPAR é€šè·¯æ¿€æ´»çš®ä¸‹è„‚è‚ªåˆ†åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317049)
- [GSE316931 æ‹Ÿå—èŠ¥ sqtl1 çªå˜ä½“çš„è½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316931)
- [GSE311093 Zeb2os é€šè¿‡æŠ‘åˆ¶ ZEB2 å†æ¿€æ´»å’Œå¿ƒè‚Œç»†èƒå»åˆ†åŒ–æ¥é˜»ç¢å¿ƒè„æ„ˆåˆ[2]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311093)
- [GSE311091 Zeb2os é€šè¿‡æŠ‘åˆ¶ ZEB2 å†æ¿€æ´»å’Œå¿ƒè‚Œç»†èƒå»åˆ†åŒ–æ¥é˜»ç¢å¿ƒè„æ„ˆåˆ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311091)
- [GSE294009 åŒ–è„“æ€§æ±—è…ºç‚æ—©æœŸå’Œæ™šæœŸçš„ç©ºé—´è½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294009)
- [GSE288782 LACTB é€šè¿‡ä¿ƒè¿› Hsc70 ä»‹å¯¼çš„ ERBB3 é™è§£æ¥æŠ‘åˆ¶è„‚è´¨åˆæˆï¼Œä»è€ŒæŠ‘åˆ¶èƒ¶è´¨ç˜¤ç”Ÿé•¿](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288782)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-05 21:51*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*